Figure 6
Figure 6. Association of donor CD4+ FOXP3+ cells with aGvHD development. Scatterplots represent Treg fractions or absolute numbers in patients before (pre) and 30 days after transplantation (d30); SD products (SD) and donors (Don). Horizontal bars indicate the median of each group. A 2-tailed, nonparametric Mann-Whitney test was applied to examine for differences between patients with no or grade I aGvHD and patients with clinically significant (≥ grade II) aGvHD development. (A) Pretransplantation CD4+ FOXP3+ content had no impact on later aGvHD development. (B) No impact of CD4+ FOXP3+ cells in SD products. (C) No impact of CD4+ FOXP3+ cells recovered 30 days after transplantation. (D) Donor CD4+ FOXP3+ cells had significant (P = .019) impact on later aGvHD development. (E,F) The absolute number of donor CD4+ CD25+ FOXP3+ cells was significantly associated with later aGvHD development (P = .045) but not the absolute number of donor CD4+ CD25− FOXP3+ cells.

Association of donor CD4+ FOXP3+ cells with aGvHD development. Scatterplots represent Treg fractions or absolute numbers in patients before (pre) and 30 days after transplantation (d30); SD products (SD) and donors (Don). Horizontal bars indicate the median of each group. A 2-tailed, nonparametric Mann-Whitney test was applied to examine for differences between patients with no or grade I aGvHD and patients with clinically significant (≥ grade II) aGvHD development. (A) Pretransplantation CD4+ FOXP3+ content had no impact on later aGvHD development. (B) No impact of CD4+ FOXP3+ cells in SD products. (C) No impact of CD4+ FOXP3+ cells recovered 30 days after transplantation. (D) Donor CD4+ FOXP3+ cells had significant (P = .019) impact on later aGvHD development. (E,F) The absolute number of donor CD4+ CD25+ FOXP3+ cells was significantly associated with later aGvHD development (P = .045) but not the absolute number of donor CD4+ CD25 FOXP3+ cells.

Close Modal

or Create an Account

Close Modal
Close Modal